Also known as TMC278 and Edurant.
Long-acting cabotegravir + rilpivirine achieved superior viral suppression versus standard oral ART at six months when initiated in people with detectable HIV.
LATA shows superiority in adolescents; OPERA real‑world suppression comparable to oral regimens; cabotegravir injections rated better than lenacapavir; EXTEND 4M tests 4‑month formulation.
